Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Float Short %

10.3

Margin Of Safety %

-47

Put/Call OI Ratio

0.06

EPS Next Q Diff

-0.42

EPS Last/This Y

-1.01

EPS This/Next Y

-0.01

Price

7.24

Target Price

7.57

Analyst Recom

2

Performance Q

130.89

Relative Volume

0.7

Beta

2.42

Ticker: FULC




21 items of 1

DateSymbolLastP/C OIP/C VolTotal OI
2025-05-08FULC5.40.080.005629
2025-05-09FULC5.390.080.005629
2025-05-12FULC5.690.090.075579
2025-05-13FULC5.80.090.005669
2025-05-14FULC5.630.080.006067
2025-05-15FULC6.60.070.006671
2025-05-16FULC6.890.060.027721
2025-05-19FULC6.920.030.297245
2025-05-20FULC6.510.030.207216
2025-05-21FULC6.250.043.087643
2025-05-22FULC6.130.050.267667
2025-05-23FULC6.440.050.017830
2025-05-27FULC6.350.050.057955
2025-05-28FULC6.90.050.068248
2025-05-29FULC7.070.050.028370
2025-05-30FULC6.870.05999.998322
2025-06-02FULC6.950.052.488321
2025-06-03FULC7.030.06999.998436
2025-06-04FULC7.020.060.258436
2025-06-05FULC7.110.060.008438
2025-06-06FULC7.240.060.008444
DateSymbolLastP/C OIP/C VolTotal OI
21 items Current Page1 of 1




21 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2025-05-08FULC5.40-134.5- -1.13
2025-05-09FULC5.37-134.5- -1.16
2025-05-12FULC5.68-134.5- -1.16
2025-05-13FULC5.79-133.6- -1.16
2025-05-14FULC5.62-133.6- -1.16
2025-05-15FULC6.60-133.6- -1.16
2025-05-16FULC6.88-133.6- -1.17
2025-05-19FULC6.93-133.9- -1.17
2025-05-20FULC6.51-133.9- -1.17
2025-05-21FULC6.25-133.9- -1.17
2025-05-22FULC6.14-133.9- -1.17
2025-05-23FULC6.45-133.9- -1.17
2025-05-27FULC6.35-133.8- -1.17
2025-05-28FULC6.89-133.8- -1.17
2025-05-29FULC7.07-133.8- -1.17
2025-05-30FULC6.88-133.8- -1.17
2025-06-02FULC6.95-133.8- -1.17
2025-06-03FULC7.03-133.8- -1.17
2025-06-04FULC7.02-133.8- -1.17
2025-06-05FULC7.11-133.8- -1.17
2025-06-06FULC7.24-133.8- -1.17
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
21 items Current Page1 of 1




21 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2025-05-08FULC0.00-11.657.45
2025-05-09FULC-0.01-11.657.45
2025-05-12FULC-0.01-10.557.11
2025-05-13FULC-0.01-10.557.11
2025-05-14FULC-0.01-10.557.11
2025-05-15FULC-0.01-10.557.11
2025-05-16FULC-0.01-10.557.11
2025-05-19FULC-0.01-8.377.11
2025-05-20FULC-0.01-8.377.11
2025-05-21FULC-0.01-8.377.11
2025-05-22FULC-0.01-8.377.11
2025-05-23FULC-0.01-8.377.11
2025-05-27FULC-0.01-3.457.11
2025-05-28FULC-0.01-3.4510.30
2025-05-29FULC-0.01-3.4510.30
2025-05-30FULC-0.01-3.4510.30
2025-06-02FULC-0.01-1.5110.30
2025-06-03FULC-0.01-1.5110.30
2025-06-04FULC-0.01-1.5110.30
2025-06-05FULC-0.01-1.5110.30
2025-06-06FULC-0.01-1.5110.30
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
21 items Current Page1 of 1

Last Quarter Act. EPS

-0.28

Avg. EPS Est. Current Quarter

-0.29

Avg. EPS Est. Next Quarter

-0.7

Insider Transactions

-0.01

Institutional Transactions

-1.51

Beta

2.42

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

3.87

Quality Score

37

Growth Score

45

Sentiment Score

54

Actual DrawDown %

78.1

Max Drawdown 5-Year %

-92.7

Target Price

7.57

P/E

Forward P/E

PEG

P/S

4.89

P/B

1.71

P/Free Cash Flow

51.77

EPS

-0.07

Average EPS Est. Cur. Y​

-1.17

EPS Next Y. (Est.)

-1.18

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-0.64

Relative Volume

0.7

Return on Equity vs Sector %

-24.3

Return on Equity vs Industry %

-6.3

EPS 1 7Days Diff

EPS 1 30Days Diff

0.08

EBIT Estimation

Fulcrum Therapeutics, Inc.
Sector: Healthcare
Industry: Biotechnology
Employees: 45
Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops small molecules to improve the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its clinical-stage product candidate is pociredir, a fetal hemoglobin inducer, which is in phase 1b clinical trial for the treatment of sickle cell disease and beta-thalassemia. The company also discovers drug targets for potential treatment inherited aplastic anemias, such as of diamond-blackfan anemia, shwachman-diamond syndrome, and fanconi anemia, as well as novel fetal hemoglobin inducers, fibrotic disorders, and cardiomyopathies which is in preclinical trial. It has collaboration and license agreement with MyoKardia, Inc. to identify biological targets that are capable of modulating genes of interest with relevance to cardiomyopathies; and licensce agreement with CAMP4 which includes certain small molecule compounds, composition of matter and method of use patent rights, and know-how to research, develop, manufacture, use, and commercialize; and Sanofi for the development and commercialization of losmapimod, an oral small molecule being investigated for the treatment of facioscapulohumeral muscular dystrophy. Fulcrum Therapeutics, Inc. was Incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
stock quote shares FULC – Fulcrum Therapeutics Inc Stock Price stock today
news today FULC – Fulcrum Therapeutics Inc stock forecast ,stock prediction 2023 2024 2025
marketwatch FULC – Fulcrum Therapeutics Inc yahoo finance google finance
stock history FULC – Fulcrum Therapeutics Inc invest stock market
stock prices FULC premarket after hours
ticker FULC fair value insiders trading